Biodesix Inc (BDSX) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.51 is considered Undervalued compared with the five-year average of -3.97. The fair price of Biodesix Inc (BDSX) is between 222.99 to 335.52 according to relative valuation method. Compared to the current price of 15.75 USD , Biodesix Inc By Undervalued By 92.94%.

Relative Value

Fair Zone

222.99-335.52

Current Price：15.75

92.94%

Undervalued

P/E

EV/EBITDA

EV/EBIT

P/S

P/OCF

P/FCF

Trailing

Forward

Unlock 5-Year Valuation Change

Is Biodesix Inc (BDSX) at a historical peak or a rare bargain? Access the full 5-year trend to find out.

Unlock Now

Biodesix Inc (BDSX) has a current Price-to-Book (P/B) ratio of -29.84. Compared to its 3-year average P/B ratio of -3.71, the current P/B ratio is approximately 704.36% higher. Relative to its 5-year average P/B ratio of 0.20, the current P/B ratio is about -15027.30% higher. Biodesix Inc (BDSX) has a Forward Free Cash Flow (FCF) yield of approximately -56.73%. Compared to its 3-year average FCF yield of -41.86%, the current FCF yield is approximately 35.53% lower. Relative to its 5-year average FCF yield of -38.42%, the current FCF yield is about 47.65% lower.

Competitors Valuation Multiple

AI Analysis

The average P/S ratio for BDSX competitors is 29.76, providing a benchmark for relative valuation. Biodesix Inc Corp (BDSX.O) exhibits a P/S ratio of 0.51, which is -98.28% above the industry average. Given its robust revenue growth of 40.76%, this premium appears sustainable.

P/E

P/S

EV/EBITDA

EV/EBIT

Earnings Growth

Market Cap

Performance Decomposition

AI Analysis

Market capitalization of BDSX increased by 0.00% over the past 1 year(s). The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00% to the performance.

Overall, the performance of BDSX in the past 1 year(s) is driven by Unknown.

People Also Watch

Frequently Asked Questions

Is BDSX currently overvalued or undervalued?

What is Biodesix Inc (BDSX) fair value?

BDSX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. The fair price of Biodesix Inc (BDSX) is between 222.99 to 335.52 according to relative valuation method.

How does BDSX's valuation metrics compare to the industry average?

The average P/S ratio for BDSX's competitors is 29.76, providing a benchmark for relative valuation. Biodesix Inc Corp (BDSX) exhibits a P/S ratio of 0.51, which is -98.28% above the industry average. Given its robust revenue growth of 40.76%, this premium appears sustainable.

What is the current P/B ratio for Biodesix Inc (BDSX) as of Mar 02 2026?

As of Mar 02 2026, Biodesix Inc (BDSX) has a P/B ratio of -29.84. This indicates that the market values BDSX at -29.84 times its book value.

What is the current FCF Yield for Biodesix Inc (BDSX) as of Mar 02 2026?

As of Mar 02 2026, Biodesix Inc (BDSX) has a FCF Yield of -56.73%. This means that for every dollar of Biodesix Inc's market capitalization, the company generates -56.73 cents in free cash flow.

What is the current Forward P/E ratio for Biodesix Inc (BDSX) as of Mar 02 2026?

As of Mar 02 2026, Biodesix Inc (BDSX) has a Forward P/E ratio of -2.25. This means the market is willing to pay $-2.25 for every dollar of Biodesix Inc's expected earnings over the next 12 months.

What is the current Forward P/S ratio for Biodesix Inc (BDSX) as of Mar 02 2026?

As of Mar 02 2026, Biodesix Inc (BDSX) has a Forward P/S ratio of 0.51. This means the market is valuing BDSX at $0.51 for every dollar of expected revenue over the next 12 months.

BDSX Valuation